Tempus AI Launches ArteraAI Prostate Test for Metastatic Prostate Cancer

Shots: Tempus AI has reported clinical launch of the ArteraAI Prostate Test (mHSPC), a CLIA-certified & CAP-accredited prognostic assay designed for pts with metastatic hormone-sensitive prostate cancer (mHSPC) ArteraAI Prostate Test (mHSPC) is an externally developed digital pathology algorithm clinically available through the Tempus AI ecosystem, with full platform integration to support personalized treatment decisions…

ByRidhi Rastogi3 hours ago

NEWS

Agilent Technologies to Acquire Biocare Medical for $950M

Shots: Agilent Technologies has entered into a definitive agreement to acquire Biocare Medical from investor groups led by Excellere Partners & GHO Capital Partners As per the deal, Agilent will acquire Biocare in an all-cash transaction valued at $950M, with closing anticipated by Q4’26, after which Biocare will become a part of the Agilent Life…

ByRidhi RastogiMarch 10, 2026

Tempus AI Launches ArteraAI Prostate Test for Metastatic Prostate Cancer

Agilent Technologies to Acquire Biocare Medical for $950M

Contact US

FOLLOW US